The CLIO Consortium: Optimization of Cerenkov Luminescence Imaging for Image-Guided Cancer Surgery Cancer is the second largest cause of death and morbidity in Europe, with more than 3 million new cases diagnosed each year. The most effective treatment strategy for most forms of cancer is early detection followed by surgery.
The CLI Project aims to evaluate the imaging technology in patients undergoing surgery for gastric cancer.
The Project is European Union funded research Programme under the Seventh Framework Programme (FP7). FP7 has been the EU’s main instrument for supporting innovative research in Europe, and has had two main strategic objectives: to strengthen the scientific and technological base of European industry and to encourage its international competitiveness, while promoting research that has supported EU policies. For more information visit http://cordis.europa.eu/fp7
Our high-end instrumentation and image analysis softwares are developed further and exploited in collaboration with Mediso as industrial partner.
Mediso Medical Imaging Systems with headquarters in Budapest is a dynamic supplier of Nuclear Medicine and modern Hybrid Imaging techniques to the health care and medical research institutions of the world. The company was founded in 1990 by experts of the largest research and manufacturing company of the region which has been engaged of nuclear equipment manufacturing since 1960.
Main activities of the company:
- Researching innovative human and pre-clinical imaging technologies
- Developing leading edge human and pre-clinical systems
- Manufacturing, servicing and selling imaging equipment
- Providing diagnostic clinical services
INSERT is a research project funded by the Seventh Framework Programme of the European Commission.
Its acronym (INSERT) stands for “Development of an integrated SPECT/MRI system for enhanced stratification of brain tumour patients prior to patient-specific radio-chemo therapy and early assessment of treatment efficacy”)
The objective of the INSERT project is in fact to develop an innovative system combining SPECT (Single Photon Emission Computed Tomography) and MRI (Magnetic Resonance Imaging), which will enable the simultaneous acquisition of images resulting from the two systems.
CROmed provides extensive normal rat and mouse brain and animal glioma heterogeneity MRI and SPECT imaging. Our results and data analysis work support specification and application-related development tasks in INSERT.